ArriVent BioPharma, Inc.
Clinical-stage biopharma developing oncology drugs for difficult-to-treat diseases.
AVBP | US
Overview
Corporate Details
- ISIN(s):
- US04272N1028
- LEI:
- Country:
- United States of America
- Address:
- 18 CAMPUS BLVD., NEWTOWN SQUARE
- Website:
- https://arrivent.com/
- Sector:
- Manufacturing
Description
ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to identifying, developing, and commercializing differentiated medicines for patients with difficult-to-treat diseases, with an initial focus on oncology. The company's strategy involves forging strategic collaborations to in-license and advance promising drug candidates for global patient populations. Its lead development candidate is firmonertinib, a novel therapeutic for cancer. ArriVent's pipeline also includes other oncology therapeutics, such as next-generation antibody drug conjugates. The company leverages its team's extensive drug development and regulatory experience to design development strategies with clear paths to approval, aiming to address significant unmet medical needs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all ArriVent BioPharma, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for ArriVent BioPharma, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for ArriVent BioPharma, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
